Transarterial chemoembolization combined with lenvatinib plus tislelizumab for unresectable hepatocellular carcinoma: a multicenter cohort study

Yushan Zhao(Shanxi Provincial Cancer Hospital), Yi Chen(Shanxi Medical University), Xiao Li(Shanghai Jiao Tong University), Dong Wang(Sichuan University), Zhi-Jun Dang(Shanxi Provincial Cancer Hospital), Duiping Feng(Shanxi Medical University), YaoQing Xue(Shanxi Provincial Cancer Hospital), ZhiYu Nan(Shanxi Provincial Cancer Hospital), Shu-Wei Wen(Shanxi Provincial Cancer Hospital)
Frontiers in Immunology
October 1, 2024
10.3389/fimmu.2024.1449663
Cited by 7

Related Papers

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)
|Signal Transduction and Targeted Therapy|2023|295
Long noncoding RNA EGFR-AS1 promotes cell growth and metastasis via affecting HuR mediated mRNA stability of EGFR in renal cancer
|Cell Death and Disease|2019|150
Extension of the <i>in vivo</i> haploid induction system from diploid maize to hexaploid wheat
|Plant Biotechnology Journal|2019|145
The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
|Frontiers in Oncology|2021|87
Tumor immunological phenotype signature-based high-throughput screening for the discovery of combination immunotherapy compounds
|Science Advances|2021|86